ArticleBMC anesthesiology2026
Evaluation of leukocyte depletion filters for the removal of EpCAM-positive tumor cells during oncologic intraoperative blood salvage using CATUVAB
Article in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntraoperative blood salvage (IBS) reduces exposure to allogeneic blood but is accompanied by concerns in oncologic surgery regarding the potential reinfusion of residual tumor cells and subsequent metastatic dissemination. The CATUVAB® procedure was developed to eliminate EpCAM-positive tumor cells from autologous erythrocyte concentrates (EC). As CATUVAB® requires integration of a leukocyte depletion filter (LDF), the present study aimed to evaluate whether three different commercially available LDF meet predefined safety and efficacy criteria within this procedure.
methodsIn this prospective ex vivo study, intraoperatively collected blood from patients undergoing major oncologic surgery was processed using the CATUVAB® procedure in combination with one of three LDF (Fresenius BioR Flex AT, Haemonetics US RS1, Puriblood LRW-50-04-PS). The primary endpoint was depletion of EpCAM-positive tumor cells. Secondary endpoints included residual catumaxomab levels in the final EC and changes in proinflammatory cytokines (IL-6, IL-8, TNF-α, IFN-γ). Removal of EpCAM/CD133 double-positive cancer stem cells was explored in a subgroup.
resultsThirty-one patients were analyzed. EpCAM-positive tumor cells were detected in intraoperative blood in a substantial proportion of samples, with marked interindividual variability in tumor cell burden. After CATUVAB® processing and final filtration, no EpCAM-positive tumor cells were detectable in any EC, irrespective of the LDF used. EpCAM/CD133 double-positive cancer stem cells were also eliminated in the subgroup. Residual catumaxomab was detectable in a proportion of ECs but consistently remained below the predefined safety threshold of 70 ng per EC. IL-6 and IL-8 levels were markedly reduced during processing across all filter types, whereas tumor necrosis factor-α (TNF-α) and interferon-gamma (IFN-γ) were largely below detection limits.
conclusionThe present study demonstrates that the CATUVAB® procedure, in combination with different leukocyte depletion filters, achieved effective removal of EpCAM-positive tumor cells, accompanied by low residual catumaxomab levels and reduced pro-inflammatory cytokine concentrations. These findings support the feasibility of this approach; however, given the limited sample size and exploratory design, they should be considered preliminary and require confirmation in larger studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.